Trial record 1 of 1 for:    PCYC-1129 | Graft-versus-host-disease
Previous Study | Return to List | Next Study

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02195869
Recruitment Status : Unknown
Verified April 2016 by Pharmacyclics LLC..
Recruitment status was:  Active, not recruiting
First Posted : July 21, 2014
Last Update Posted : April 14, 2016
Information provided by (Responsible Party):
Pharmacyclics LLC.

Brief Summary:
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Drug: Ibrutinib Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
Study Start Date : July 2014
Estimated Primary Completion Date : December 2017

Arm Intervention/treatment
Experimental: Phase 1b: Dose Level 1
Ibrutinib PO administered daily
Drug: Ibrutinib
Other Name: PCI32765

Experimental: Phase 1b: Dose Level 2
Ibrutinib (PO) administered daily
Drug: Ibrutinib
Other Name: PCI32765

Experimental: Phase 1b: Dose Level 3
Ibrutinib (PO) administered daily
Drug: Ibrutinib
Other Name: PCI32765

Experimental: Phase 2
Ibrutinib (PO) administered daily for 18 months
Drug: Ibrutinib
Other Name: PCI32765

Primary Outcome Measures :
  1. Phase 1b: Number of dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib [ Time Frame: 28 treatment days after last subject enrolled in Phase 1 dose level(s). ]
  2. Phase 2 (Efficacy): Overall cGVHD response rate defined as the proportion of evaluable subjects who achieve a [NIH-defined Complete Response (CR) and Partial Response (PR)] over all subjects who were treated with RP2D [ Time Frame: When the last subject completes 6 months of treatment. ]

Secondary Outcome Measures :
  1. Failure Free Survival (FFS) [ Time Frame: When the last subject completes 6 and 12 months of treatment. ]
  2. Change in symptom burden by the Lee cGVHD Symptom Scale [ Time Frame: Approximately 18 months after last subject is enrolled or up to disease progression, whichever occurs first. ]
  3. Corticosteroid requirement changes over Time [ Time Frame: Approximately 18 months after last subject is enrolled or up to disease progression, whichever occurs first. ]
  4. Number of subjects with Adverse Events (AE) as a measure of safety and tolerability of ibrutinib [ Time Frame: Approximately 18 months after last subject is enrolled. ]
  5. Determine the plasma pharmacokinetics of ibrutinib and the metabolite, PCI-45227 [ Time Frame: Samples will be collected during the first two weeks of subject receiving study drug and will be assessed approximately 1 month after completion of the PK sample collections of the last subject enrolled at each dose level. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Steroid dependent or refractory classic chronic GVHD disease.
  • No more than 3 previous treatments for cGVHD.
  • Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.
  • Men and women ≥18 years old.
  • Karnofsky performance status ≥60.

Exclusion Criteria:

  • Known or suspected active acute GVHD.
  • Current treatment with sirolimus AND either cyclosporine or tacrolimus.
  • History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug.
  • Currently active, clinically significant cardiovascular disease.
  • Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.
  • Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
  • History of other malignancy (not including the underlying malignancy that was the indication for transplant)
  • Concomitant use of warfarin or other Vitamin K antagonists
  • Known bleeding disorders or hemophilia.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).
  • Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02195869

United States, California
City of Hope Medical Center
Duarte, California, United States, 91010
University of California, San Francisco
San Francisco, California, United States, 94143
Stanford University
Stanford, California, United States, 94305
United States, Georgia
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
United States, Tennessee
Vanderbilt University Medical Center, Henry-Joyce Cancer Clinic
Nashville, Tennessee, United States, 37232
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Pharmacyclics LLC.
Study Director: Lori Styles, MD Pharmacyclics LLC.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pharmacyclics LLC. Identifier: NCT02195869     History of Changes
Other Study ID Numbers: PCYC-1129-CA
First Posted: July 21, 2014    Key Record Dates
Last Update Posted: April 14, 2016
Last Verified: April 2016

Keywords provided by Pharmacyclics LLC.:
graft versus host disease
chronic graft versus host disease
Steroid dependent

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases